【大摩:药明合联(02268.HK)新加坡工厂投入营运 目标价60港元 评级“增持”】智通财经APP获悉,摩根士丹利发布

智通财经
07 Jul
【大摩:药明合联(02268.HK)新加坡工厂投入营运 目标价60港元 评级“增持”】智通财经APP获悉,摩根士丹利发布研报称,予药明合联(02268.HK)目标价60港元,评级为“增持”。报告指,集团宣布新加坡工厂全面投入营运,预计将于2026年初投入GMP生产。截至今年5月,该公司已获得8项PPQ(制程性能鉴定)。大摩认为,该工厂的竣工预示着两个趋势:为即将到来的商业化阶段合约做好准备;双重采购,提升供应链韧性。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10